Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;123(3):532-542.
doi: 10.1002/jcb.30196. Epub 2021 Dec 21.

The emerging role of selenium metabolic pathways in cancer: New therapeutic targets for cancer

Kalishwaralal Kalimuthu  1   2 , Chenicheri K Keerthana  2 , Manikandan Mohan  3   4 , Jaison Arivalagan  5 , Johnson Retnaraj Samuel Selvan Christyraj  6 , Michael A Firer  7   8   9 , Mohammad Haroon Asif Choudry  1 , Ruby John Anto  2 , Yong J Lee  1
Affiliations
Review

The emerging role of selenium metabolic pathways in cancer: New therapeutic targets for cancer

Kalishwaralal Kalimuthu et al. J Cell Biochem. 2022 Mar.

Abstract

Selenium (Se) is incorporated into the body via the selenocysteine (Sec) biosynthesis pathway, which is critical in the synthesis of selenoproteins, such as glutathione peroxidases and thioredoxin reductases. Selenoproteins, which play a key role in several biological processes, including ferroptosis, drug resistance, endoplasmic reticulum stress, and epigenetic processes, are guided by Se uptake. In this review, we critically analyze the molecular mechanisms of Se metabolism and its potential as a therapeutic target for cancer. Sec insertion sequence binding protein 2 (SECISBP2), which is a positive regulator for the expression of selenoproteins, would be a novel prognostic predictor and an alternate target for cancer. We highlight strategies that attempt to develop a novel Se metabolism-based approach to uncover a new metabolic drug target for cancer therapy. Moreover, we expect extensive clinical use of SECISBP2 as a specific biomarker in cancer therapy in the near future. Of note, scientists face additional challenges in conducting successful research, including investigations on anticancer peptides to target SECISBP2 intracellular protein.

Keywords: cancer therapy; glutathione peroxidase-4; selenocysteine; selenocysteine insertion sequence binding protein 2; thioredoxin reductase 1.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests

The authors declare no competing financial interests.

Figures

Figure 1:
Figure 1:
Graphical illustration of the role of selenium in augmenting drug resistance in cancer cells under A. in vitro and B. in vivo (via ferroptosis) conditions. (Created by Biorender.com).
Figure 2:
Figure 2:
Diagrammatic representation of the molecular mechanisms which manifest SECISBP2 as a potential therapeutic target for cancer treatment. (Created by Biorender.com).
Figure 3:
Figure 3:
Phage display peptide library (PDPL) - Biopanning techniques for particular target molecules (created by Biorender.com).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. AA T, G B, AV S, A H, MG S, S C, J A. 2018. The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker? Cell Mol Life Sci 75(9):1567–1586. - PMC - PubMed
    1. Arnér E 2021. The selenoprotein thioredoxin reductase 1 (TrxR1, TXNRD1) as a main regulator of growth factor responses. Free Radic Biol Med 165:5–6.
    1. Arnér ESJ. 2020. Perspectives of TrxR1-based cancer therapies. Oxidative Stress Eustress Distress 639–667.
    1. Bakhshinejad B, Sadeghizadeh M. 2016. A polystyrene binding target-unrelated peptide isolated in the screening of phage display library. Anal Biochem 512. - PubMed
    1. Bashari O, Redko B, Cohen A, Luboshits G, Gellerman G, Firer MA. 2017. Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells. Cancer Lett 408. - PubMed

Publication types

MeSH terms

LinkOut - more resources

-